Pharma Focus Asia

Cambrex Invests US$16.5 million to Open New R&D Facility

Introduction:
Cambrex  plans to open new R&D manufacturing facility in Minneapolis, USA. It will be located near the Minneapolis–St. Paul Airport.

Features:
The project includes construction of new r&d facility and multi phase expansion.

The new r&d facility will be laid with an area covering of 21,000-square-foot to expand capacity for small molecule development and manufacturing. In addition, multi-phase, 9,000-square-foot expansion and a 21,000-square-foot renovation are also part of the project.

The exapnsion adds a new quality control laboratory and administrative office space. Moreover, the rennovation modernises the current quality control and research and development facilities.

The facility specialised in analytical and chemical process development for pharmaceutical drug candidates will be an extension for Cambrex’s flagship facility in Charles City, Iowa. The new R & D facility is expected to add 40 new jobs in the coming 2-3 years.

Specifications:

NameCambrex
TypeNew Construction
BudgetUS$16.5 million

 

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference